{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:59:05Z","timestamp":1793383145950,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2006,12,1]],"date-time":"2006-12-01T00:00:00Z","timestamp":1164931200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2006,12]]},"DOI":"10.1007\/s00467-006-0270-8","type":"journal-article","created":{"date-parts":[[2006,10,12]],"date-time":"2006-10-12T15:14:16Z","timestamp":1160666056000},"page":"1824-1829","source":"Crossref","is-referenced-by-count":37,"title":["The effect of aldosterone blockade in patients with Alport syndrome"],"prefix":"10.1007","volume":"21","author":[{"given":"Hiroshi","family":"Kaito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Yoshiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoko","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Przybyslaw Krol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norishige","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,12,1]]},"reference":[{"key":"270_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1007\/s004670050804","volume":"14","author":"CE Kashtan","year":"2000","unstructured":"Kashtan CE (2000) Alport syndromes: phenotypic heterogeneity of progressive hereditary nephritis. Pediatr Nephrol 14:502\u2013512","journal-title":"Pediatr Nephrol"},{"key":"270_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/01.ASN.0000046964.15831.16","volume":"14","author":"D Chen","year":"2003","unstructured":"Chen D, Jefferson B, Harvey SJ, Zheng K, Gartley CJ, Jacobs RM, Thorner PS (2003) Cyclosporine A slows the progressive renal disease of Alport syndrome (X-linked hereditary nephritis): results from a canine model. J Am Soc Nephrol 14:690\u2013698","journal-title":"J Am Soc Nephrol"},{"key":"270_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/BF00866293","volume":"6","author":"L Callis","year":"1992","unstructured":"Callis L, Vila A, Nieto J, Fortuny G (1992) Effect of cyclosporine A on proteinuria in patients with Alport\u2019s syndrome. Pediatr Nephrol 6:140\u2013144","journal-title":"Pediatr Nephrol"},{"key":"270_CR4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1046\/j.1523-1755.1999.0550031051.x","volume":"55","author":"L Callis","year":"1999","unstructured":"Callis L, Vila A, Carrera M, Nieto J (1999) Long-term effects of cyclosporine A in Alport\u2019s syndrome. Kidney Int 55:1051\u20131056","journal-title":"Kidney Int"},{"key":"270_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0021-9975(97)80016-3","volume":"117","author":"KM Grodecki","year":"1997","unstructured":"Grodecki KM, Gains MJ, Baumal R, Osmond DH, Cotter B, Valli VE, Jacobs RM (1997) Treatment of X-linked hereditary nephritis in Samoyed dogs with angiotensin converting enzyme (ACE) inhibitor. J Comp Pathol 117:209\u2013225","journal-title":"J Comp Pathol"},{"key":"270_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/S0272-6386(96)90540-5","volume":"27","author":"EP Cohen","year":"1996","unstructured":"Cohen EP, Lemann J Jr (1996) In hereditary nephritis angiotensin-converting enzyme inhibition decreases proteinuria and may slow the rate of progression. Am J Kidney Dis 27:199\u2013203","journal-title":"Am J Kidney Dis"},{"key":"270_CR7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","volume":"63","author":"O Gross","year":"2003","unstructured":"Gross O, Beirowski B, Koepke ML, Kuck J, Reiner M, Addicks K, Smyth N, Schulze-Lohoff E, Weber M (2003) Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int 63:438\u2013446","journal-title":"Kidney Int"},{"key":"270_CR8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00467-003-1366-z","volume":"19","author":"W Proesmans","year":"2004","unstructured":"Proesmans W, Dyck MV (2004) Enarapril in children with Alport syndrome. Pediatr Nephrol 19:271\u2013275","journal-title":"Pediatr Nephrol"},{"key":"270_CR9","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s004310051301","volume":"159","author":"W Proesmans","year":"2000","unstructured":"Proesmans W, Knockaert H, Trouet D (2000) Enarapril in paediatric patients with Alport syndrome: 2 years\u2019 experience. Eur J Pediatr 159:430\u2013433","journal-title":"Eur J Pediatr"},{"key":"270_CR10","unstructured":"Inoue M, Nomura S, Naito I, Ishikawa E, Katayama K, Oosugi K, Nakano T (2005) Renoprotection of angiotensin II receptor blocking agent for Alport\u2019s mice. Abstract from American Society of Nephrology Renal Week 2005, 8\u201313 November 2005, Philadelphia"},{"key":"270_CR11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/S0272-6386(01)80115-3","volume":"37","author":"M Epstein","year":"2001","unstructured":"Epstein M (2001) Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37:677\u2013688","journal-title":"Am J Kidney Dis"},{"key":"270_CR12","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1093\/ndt\/gfg339","volume":"18","author":"M Epstein","year":"2003","unstructured":"Epstein M (2003) Aldosterone receptor blockade and the role of eplerenone: evolving perspectives (2003) Nephrol Dial Transplant 18:1984\u20131992","journal-title":"Nephrol Dial Transplant"},{"key":"270_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou A, Becker G (2001) Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345:925\u2013926","journal-title":"N Engl J Med"},{"key":"270_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","volume":"41","author":"A Sato","year":"2003","unstructured":"Sato A, Hayashi K, Naruse M, Saruta T (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41:64\u201368","journal-title":"Hypertension"},{"key":"270_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T (2005) Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 18:44\u201349","journal-title":"Am J Hypertens"},{"key":"270_CR16","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, Roniker B, Patrick JL, Krause SL (2004) Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol 93:990\u2013996","journal-title":"Am J Cardiol"},{"key":"270_CR17","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1038\/ki.1996.459","volume":"50","author":"CE Kashtan","year":"1996","unstructured":"Kashtan CE, Michael AF (1996) Alport syndrome. Kidney Int 50:1445\u20131463","journal-title":"Kidney Int"},{"key":"270_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000424804","volume":"117","author":"MC Gregory","year":"1996","unstructured":"Gregory MC, Terreros DA, Barker DF, Fain PN, Denison JC, Atkin CL (1996) Alport syndrome - clinical phenotypes, incidence, and pathology. Contrib Nephrol 117:1\u201328","journal-title":"Contrib Nephrol"},{"key":"270_CR19","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1111\/j.1523-1755.2004.00560.x","volume":"65","author":"C Pescucci","year":"2004","unstructured":"Pescucci C, Mari F, Longo I, Vogiatzi P, Caselli R, Scala E, Abaterusso C, Gusmano MS, Miglietti N, Bresin E, Renieri A (2004) Autosomal-dominant Alport syndrome: natural history of a disease due to COL4A3 or COL4A4 gene. Kidney Int 65:1598\u20131603","journal-title":"Kidney Int"},{"key":"270_CR20","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/path.1711350305","volume":"135","author":"N Yoshikawa","year":"1981","unstructured":"Yoshikawa N, Cameron AH, White RH (1981) The glomerular basal lamina in hereditary nephritis. J Pathol 135:199\u2013209","journal-title":"J Pathol"},{"key":"270_CR21","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJM198312223092503","volume":"309","author":"JM Ginsberg","year":"1983","unstructured":"Ginsberg JM, Chang BS, Matarese RA, Garella S (1983) Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309:1543\u20131546","journal-title":"N Engl J Med"},{"key":"270_CR22","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S0022-3476(05)82881-1","volume":"116","author":"C Abitbol","year":"1990","unstructured":"Abitbol C, Zilleruelo G, Freundlich M, Strauss J (1990) Quantitation of proteinuria with urinary protein\/creatinine ratios and random testing with dipsticks in nephrotic children. J Pediatr 116:243\u2013247","journal-title":"J Pediatr"},{"key":"270_CR23","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0272-6386(03)00826-6","volume":"42","author":"G Eknoyan","year":"2003","unstructured":"Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R (2003) Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute if diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42:617\u2013622","journal-title":"Am J Kidney Dis"},{"key":"270_CR24","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1542\/peds.58.2.259","volume":"58","author":"GJ Schwartz","year":"1976","unstructured":"Schwartz GJ, Haycock MB, Edelmann CM Jr., Spizer A (1976) A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259\u2013263","journal-title":"Pediatrics"},{"key":"270_CR25","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0022-3476(85)80697-1","volume":"106","author":"GJ Schwartz","year":"1985","unstructured":"Schwartz GJ, Gauthier B (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106:522\u2013526","journal-title":"J Pediatr"},{"key":"270_CR26","first-page":"111A","volume":"14","author":"M Charbit","year":"2003","unstructured":"Charbit M, Dechaux M, Gagnadoux MF (2003) Cyclosporine A therapy in Alport syndrome. J Am Soc Nephrol 14:111A","journal-title":"J Am Soc Nephrol"},{"key":"270_CR27","doi-asserted-by":"publisher","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"A Chrysostomou","year":"2006","unstructured":"Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ (2006) Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 1:256\u2013262","journal-title":"Clin J Am Soc Nephrol"},{"key":"270_CR28","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1161\/01.HYP.35.5.1078","volume":"35","author":"Y Sun","year":"2000","unstructured":"Sun Y, Zhang J, Zhang JQ, Ramires FJ (2000) Local angiotensin II and transforming growth factor beta 1 renal fibrosis of rats. Hypertension 35:1078\u20131084","journal-title":"Hypertension"},{"key":"270_CR29","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, Blomme EAG, Polly ML, McMahon EG (2003) Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63:1791\u20131800","journal-title":"Kidney Int"},{"key":"270_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1161\/01.HYP.0000118519.66430.22","volume":"43","author":"A Nishiyama","year":"2004","unstructured":"Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiomoto H, Shokoji T, Kimura S, Kohno M, Abe Y (2004) Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone\/salt induced hypertensive rats. Hypertension 43:841\u2013884","journal-title":"Hypertension"},{"key":"270_CR31","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2337\/diab.43.1.95","volume":"43","author":"M Wakisaka","year":"1994","unstructured":"Wakisaka M, Spiro MJ, Spiro RG (1994) Synthesis of type IV collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes 43:95\u2013103","journal-title":"Diabetes"},{"key":"270_CR32","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the randomized Aldosterone Evaluation Study. N Engl J Med 351:543\u2013551","journal-title":"N Engl J Med"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-006-0270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-006-0270-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-006-0270-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-006-0270-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T09:35:18Z","timestamp":1683624918000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-006-0270-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["270"],"URL":"https:\/\/doi.org\/10.1007\/s00467-006-0270-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,12]]}}}